Provided by Tiger Trade Technology Pte. Ltd.

Pyxis Oncology, Inc.

3.27
-0.1100-3.25%
Post-market: 3.270.00000.00%16:37 EDT
Volume:738.34K
Turnover:2.43M
Market Cap:272.74M
PE:-2.33
High:3.44
Open:3.42
Low:3.18
Close:3.38
52wk High:5.55
52wk Low:1.03
Shares:83.41M
Float Shares:49.56M
Volume Ratio:0.39
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4029
EPS(LYR):-1.2813
ROE:-179.10%
ROA:-62.95%
PB:23.84
PE(LYR):-2.55

Loading ...

Wedbush bullish on Pyxis Oncology, initiates with an Outperform

TIPRANKS
·
May 05

Wedbush Initiates Pyxis Oncology at Outperform With $6 Price Target

MT Newswires Live
·
May 05

Pyxis Oncology Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $6

THOMSON REUTERS
·
May 05

Pyxis Oncology announces annual shareholder meeting notice

Reuters
·
Apr 30

Pyxis Oncology amends 8-K to disclose CEO Lara Sullivan separation agreement

Reuters
·
Apr 30

Pyxis Oncology presents new MICVO preclinical combo data supporting ongoing pembrolizumab trial

Reuters
·
Apr 18

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

GlobeNewswire
·
Apr 18

Pyxis Oncology (PYXS) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Mar 28

Pyxis Oncology; Director Rachel Humphrey disposes of common shares worth $16,682

Reuters
·
Mar 26

Pyxis Oncology Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 24

RBC Capital Remains a Buy on Pyxis Oncology (PYXS)

TIPRANKS
·
Mar 24

Pyxis Oncology price target lowered to $8 from $9 at Stifel

TIPRANKS
·
Mar 24

Pyxis Oncology Q4 EPS $(0.29) Beats $(0.33) Estimate, Sales $11.038M

Benzinga Earnings
·
Mar 23

Pyxis Oncology FY 2025 R&D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million

Reuters
·
Mar 23

BRIEF-Pyxis Oncology FY Net Income USD -79.621 Million

Reuters
·
Mar 23

Pyxis Oncology FY EPS USD -1.28

THOMSON REUTERS
·
Mar 23

Pyxis Oncology Inc - Updated Data From Micvo Phase 1 Monotherapy Study Expected Mid-Year 2026

THOMSON REUTERS
·
Mar 23

Pyxis Oncology Inc - Expects Cash Runway Into Fourth Quarter of 2026

THOMSON REUTERS
·
Mar 23

Pyxis Oncology Inc - Updated Data From Micvo Phase 1/2 Combination Study With Keytruda Expected 2H 2026

THOMSON REUTERS
·
Mar 23

Press Release: Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Dow Jones
·
Mar 23